High Generic Drug Costs To Benefit Manufacturers But Not Consumers

BMI View: High generic drug prices will affect the listing of innovative drugs on Australia's Pharmaceutical Benefit Scheme (PBS) as the government is concerned about expenditure on subsidised medicines. This will be negative for consumers if new drugs are prevented from listing, but positive for generic drugmakers as they can capitalise on higher profit margins.

To read the full article, please choose one of the following options: